Contingent consideration

12 Months Ended

Jun. 30, 2025

Note 15. Contingent consideration


	2025 A$’000		2024 A$’000
Current Liabilities
Contingent consideration - EVT801		—		3,253
		—		3,253

Non-current Liabilities
Contingent consideration - Paxalisib		—		1,266
Contingent consideration - EVT801		—		2,486
		—		3,752
		—		7,005

Reconciliations

Reconciliation of the balance at the beginning and end of the reporting period is set out be

low:


	2025			2024
	A$’000			A$’000
Contingent consideration at start of period (current and non-current)		7,005			6,871
Interest on unwinding of discount		232			339
Foreign currency loss / (gain)		317			(86	)
Gain on remeasurement of contingent consideration		(7,554	)		(119	)

		—			7,005

Contingent consideration - Paxalisib

The total amount of milestone payments not recognised

as a liability

at year end for Paxalisib totals US$1,000,000 (A$2,776718) (2024: nil). Refer to Note 11.

Contingent consideration - EVT801

The total amount of milestone payments not recognised as a liability at year end for

EVT-801

totals €306,000,000 (A$547,798,067) (2024: €300,500,000 (A$496,287,928)). Refer to Note 11.